Press release
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from AROHSD1001, an
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH). The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021.\n\nKey data presented include the following:\n\nPharmacodynamic Response\n\n\nDose-dependent pharmacodynamic effect on hepatic HSD17B13 mRNA was observed in all patients\n\n\nAt 200 mg, all patients showed greater than 90% mRNA reductions\n\n\n\n\nHepatic HSD17B13 protein levels were reduced at all ARO-HSD dose levels, with multiple measurements below the assay’s lower limit of quantitation\n\n\nDecreases in ALT and AST were observed at doses of 100 mg ARO-HSD and greater\n\n\n9 of 18 patients had liver fat reductions on MRI-PDFF of 4-41%\n\n\n6 of 18 patients had reduction in liver stiffness (kPa) on FibroScan of 4-37%\n\n\nPharmacodynamic effect was not impacted by HSD17B13 (rs72613567, T>TA) or PNPLA3 (rs738409, C>G) mutations\n\n\nSafety\n\n\nARO-HSD was well-tolerated in patients, with no ARO-HSD-related serious adverse events reported, no adverse events leading to drug discontinuations, and no ARO-HSD-related clinically significant adverse laboratory trends observed\n\n\nOne treatment emergent serious adverse event of soft tissue injury that required hospitalization was reported in cohort 4b. This event was considered unrelated to study drug\n\n\nA copy of the poster may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\nARO-HSD is an investigational RNAi therapeutic targeting HSD17B13 as a potential treatment for patients with alcohol-related and nonalcohol related liver diseases, such as NASH. HSD17B13 is a member of the hydroxysteroid dehydrogenase family involved in the metabolism of hormones, fatty acids, and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against alcoholic hepatitis, cirrhosis,...